泊马度胺改善了骨髓瘤患者的免疫特征。 - Suppr

Suppr

超能文献

Pomalidomide improved immune profiles in myeloma.

作者信息

Seah Hannah, Bade Vaishnavi Reddy, Potluri Lakshmi Bhavani, Talluri Srikanth, Prabhala Rao H

机构信息

Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Harvard Medical School, Boston, MA 02115, USA.

出版信息

Oncoscience. 2025 Jan 14;12:1-2. doi: 10.18632/oncoscience.612. eCollection 2025.

DOI:10.18632/oncoscience.612

PMID:39839313

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11745483/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/846e/11745483/7a7beee5078e/oncoscience-12-612-g001.jpg

相似文献

Pomalidomide improved immune profiles in myeloma.泊马度胺改善了骨髓瘤患者的免疫特征。

Oncoscience. 2025 Jan 14;12:1-2. doi: 10.18632/oncoscience.612. eCollection 2025.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。

Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.基于泊马度胺和地塞米松的方案治疗难治性/复发性多发性骨髓瘤

Ther Adv Hematol. 2022 May 13;13:20406207221090089. doi: 10.1177/20406207221090089. eCollection 2022.

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.树突状细胞与泊马度胺协同抗骨髓瘤作用的小鼠骨髓瘤模型研究。

Front Immunol. 2018 Aug 3;9:1798. doi: 10.3389/fimmu.2018.01798. eCollection 2018.

Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma.泊马度胺在多发性骨髓瘤中耐药机制的多组学研究

Front Oncol. 2023 Sep 19;13:1264422. doi: 10.3389/fonc.2023.1264422. eCollection 2023.

Pomalidomide in the management of relapsed multiple myeloma.泊马度胺在复发性多发性骨髓瘤治疗中的应用。

Future Oncol. 2016 Sep;12(17):1975-83. doi: 10.2217/fon-2016-0184. Epub 2016 Jun 10.

Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.泊马度胺联合万珂和地塞米松治疗复发/难治性多发性骨髓瘤患者时对NK、NKT及B/T细胞亚群的免疫调节作用及其与无进展生存期改善的关联

Front Oncol. 2023 Dec 4;13:1271807. doi: 10.3389/fonc.2023.1271807. eCollection 2023.

Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.泊马度胺、硼替佐米和低剂量地塞米松联合治疗复发/难治性多发性骨髓瘤患者的泊马度胺群体药代动力学和暴露反应分析。

J Clin Pharmacol. 2020 Aug;60(8):1061-1075. doi: 10.1002/jcph.1602. Epub 2020 Mar 13.

Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.达雷妥尤单抗治疗后复发多发性骨髓瘤中基于卡非佐米/泊马度胺方案的疗效：加拿大骨髓瘤研究组数据库分析

Eur J Haematol. 2023 Nov;111(5):815-823. doi: 10.1111/ejh.14082. Epub 2023 Aug 13.

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松单药治疗既往治疗的多发性骨髓瘤（APOLLO）：一项开放标签、随机、III 期临床试验。

Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.

本文引用的文献

Front Oncol. 2023 Dec 4;13:1271807. doi: 10.3389/fonc.2023.1271807. eCollection 2023.

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.共识指南和建议，用于多发性骨髓瘤的感染预防：国际骨髓瘤工作组的报告。

Lancet Haematol. 2022 Feb;9(2):e143-e161. doi: 10.1016/S2352-3026(21)00283-0.

Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.泊马度胺、地塞米松和达雷妥尤单抗治疗复发/难治性多发性骨髓瘤患者的免疫调节作用。

Clin Cancer Res. 2020 Nov 15;26(22):5895-5902. doi: 10.1158/1078-0432.CCR-20-1781. Epub 2020 Sep 14.

Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma.靶向白细胞介素-17A治疗多发性骨髓瘤：骨髓瘤一种潜在的新型治疗方法。

Leukemia. 2016 Feb;30(2):379-89. doi: 10.1038/leu.2015.228. Epub 2015 Aug 21.

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.泊马度胺治疗骨髓瘤给药策略的临床及药效学分析：免疫激活及脑啡肽酶靶点的影响

Blood. 2015 Jun 25;125(26):4042-51. doi: 10.1182/blood-2014-11-611426. Epub 2015 Apr 13.

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).免疫调节剂来那度胺和泊马度胺通过调节 E3 泛素连接酶复合物 CRL4(CRBN)，诱导 T 细胞抑制因子 Ikaros 和 Aiolos 的降解，从而共同刺激 T 细胞。

Br J Haematol. 2014 Mar;164(6):811-21. doi: 10.1111/bjh.12708. Epub 2013 Dec 13.

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.TH17 细胞产生的白细胞介素-17 促进骨髓瘤细胞生长并抑制多发性骨髓瘤中的免疫功能。

Blood. 2010 Jul 1;115(26):5385-92. doi: 10.1182/blood-2009-10-246660. Epub 2010 Apr 15.

Dysfunctional T regulatory cells in multiple myeloma.多发性骨髓瘤中功能失调的调节性T细胞。

Blood. 2006 Jan 1;107(1):301-4. doi: 10.1182/blood-2005-08-3101. Epub 2005 Sep 8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验